阅读说明：本技术 对cd137和pd-l1特异性的新型融合蛋白 (Novel fusion proteins specific for CD137 and PD-L1 ) 是由 M·帕夫利杜 L·帕塔里尼 A·斯科勒-达希雷尔 C·罗特 S·奥威尔 R·贝莱巴 M· 于 2019-07-31 设计创作，主要内容包括：本发明提供对CD137和PD-L1特异性的融合蛋白,其中融合蛋白能够用于以PD-L1靶标依赖性方式共刺激淋巴细胞活化。这种融合蛋白可用于许多制药应用中,例如作为用于治疗或预防诸如各种肿瘤的人疾病的抗癌剂和/或免疫调节剂。本发明还涉及制备本文所述的融合蛋白以及包含这种融合蛋白的组合物的方法。本发明进一步涉及编码这种融合蛋白的核酸分子和用于产生这种融合蛋白和核酸分子的方法。此外,本申请公开了这些融合蛋白以及包含一种或多种这种融合蛋白的组合物的治疗性和/或诊断性用途。(The present invention provides fusion proteins specific for CD137 and PD-L1, wherein the fusion proteins are capable of being used to co-stimulate lymphocyte activation in a PD-L1 target-dependent manner. Such fusion proteins are useful in a number of pharmaceutical applications, for example as anti-cancer and/or immunomodulatory agents for the treatment or prevention of human diseases such as various tumors. The invention also relates to methods of making the fusion proteins described herein and compositions comprising such fusion proteins. The invention further relates to nucleic acid molecules encoding such fusion proteins and methods for producing such fusion proteins and nucleic acid molecules. Furthermore, the present application discloses therapeutic and/or diagnostic uses of these fusion proteins and compositions comprising one or more of such fusion proteins.)

具体实施方式

的等同物。以下的权利要求意欲涵盖这些等同物。在本说明书中提到的所有出版物、专利和专利申请在此引入本说明书中作为参考，就像每个单独的出版物、专利或专利申请具体地且分别指出引入本文作为参考一样。

V.非专利参考文献

1.GATO-CANAS，M.，ZUAZO，M.，ARASANZ，H.，IBANEZ-VEA，M.，LORENZO，L.，FERNANDEZ-HINOJAL，G.，VERA，R.，SMERDOU，C.，MARTISOVA，E.，AROZARENA，I.，WELLBROCK，C.，LLOPIZ，D.，RUIZ，M.，SAROBE，P.，BRECKPOT，K.，KOCHAN，G.&ESCORS，D.2017.PDL1Signals through Conserved Sequence Motifs to Overcome Interferon-MediatedCytotoxicity.Cell Rep，20，1818-1829.

2.KARWACZ，K.，BRICOGNE，C.，MACDONALD，D.，ARCE，F.，BENNETT，C.L.，COLLINS，M.&ESCORS，D.2011.PD-L1 co-stimulation contributes to ligand-induced T cellreceptor down-modulation on CD8+T cells.EMBO Mol Med，3，581-92.

3.ARASANZ，H.，GATO-CANAS，M.，ZUAZO，M.，IBANEZ-VEA，M.，BRECKPOT，K.，KOCHAN，G.&ESCORS，D.2017.PD1 signal transduction pathways in T cells.Oncotarget，8，51936-51945.

4.PATSOUKIS，N.，BARDHAN，K.，CHATTERJEE，P.，SARI，D.，LIU，B.，BELL，L.N.，KAROLY，E.D.，FREEMAN，G.J.，PETKOVA，V.，SETH，P.，LI，L.&BOUSSIOTIS，V.A.2015.PD-1alters T-cell metabolic reprogramming by inhibiting glycolysis and promotinglipolysis and fatty acid oxidation.Nat Commun，6，6692.

5.XU-MONETTE，Z.Y.，ZHANG，M.，LI，J.&YOUNG，K.H.2017.PD-1/PD-L1 Blockade：Have We Found the Key to Unleash the Antitumor Immune Response？Front Immunol，8，1597.

6.LI，S.Y.&LIU，Y.2013.Immunotherapy of melanoma with the immunecostimulatory monoclonal antibodies targeting CD137.Clin Pharmacol，5，47-53.

7.SNELL，L.M.，LIN，G.H.，MCPHERSON，A.J.，MORAES，T.J.&WATTS，T.H.2011.T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancerimmunotherapy.Immunol Rev，244，197-217.

8.WYZGOL，A.，MULLER，N.，FICK，A.，MUNKEL，S.，GRIGOLEIT，G.U.，PFIZENMAIER，K.&WAJANT，H.2009.Trimer stabilization，oligomerization，and antibody-mediatedcell surface immobilization improve the activity of soluble trimers of CD27L，CD40L，41BBL，and glucocorticoid-induced TNF receptor ligand.J Immunol，183，1851-61.

9.YAO，S.，ZHU，Y.&CHEN，L.2013.Advances in targeting cell surfacesignalling molecules for immune modulation.Nat Rev Drug Discov，12，130-46.

10.MELERO，I.，BACH，N.，HELLSTROM，K.E.，ARUFFO，A.，MITTLER，R.S.&CHEN，L.1998.Amplification of tumor immunity by gene transfer of the co-stimulatory4-1BB ligand：synergy with the CD28 co-stimulatory pathway.Eur J Immunol，28，1116-21.

11.YANG，Y.，YANG，S.，YE，Z.，JAFFAR，J.，ZHOU，Y.，CUTTER，E.，LIEBER，A.，HELLSTROM，I.&HELLSTROM，K.E.2007.Tumor cells expressing anti-CD137 scFv inducea tumor-destructive environment.Cancer Res，67，2339-44.

12.ZHANG，H.，KNUTSON，K.L.，HELLSTROM，K.E.，DISIS，M.L.&HELLSTROM，I.2006.Antitumor efficacy of CD137 ligation is maximized by the use of aCD137 single-chain Fv-expressing whole-cell tumor vaccine compared withCD137-specific monoclonal antibody infusion.Mol Cancer Ther，5，149-55.

13.YE，Z.，HELLSTROM，I.，HAYDEN-LEDBETTER，M.，DAHLIN，A.，LEDBETTER，J.A.&HELLSTROM，K.E.2002.Gene therapy for cancer using single-chain Fv fragmentsspecific for 4-1BB.Nat Med，8，343-8.

14.MARTINET，O.，DIVINO，C.M.，ZANG，Y.，GAN，Y.，MANDELI，J.，THUNG，S.，PAN，P.Y.&CHEN，S.H.2002.T cell activation with systemic agonistic antibody versuslocal 4-1BB ligand gene delivery combined with interleukin-12 eradicate livermetastases of breast cancer.Gene Ther，9，786-92.

15.YE，Q.，SONG，D.G.，POUSSIN，M.，YAMAMOTO，T.，BEST，A.，LI，C.，COUKOS，G.&POWELL，D.J.，JR.2014.CD137 accurately identifies and enriches for naturallyoccurring tumor-reactive T cells in tumor.Clin Cancer Res，20，44-55.

16.CHACON，J.A.，WU，R.C.，SUKHUMALCHANDRA，P.，MOLLDREM，J.J.，SARNAIK，A.，PILON-THOMAS，S.，WEBER，J.，HWU，P.&RADVANYI，L.2013.Co-stimulation through 4-1BB/CD137improves the expansion and function of CD8(+)melanoma tumor-infiltratinglymphocytes for adoptive T-cell therapy.PLoS One，8，e60031.

17.FISHER，T.S.，KAMPERSCHROER，C.，OLIPHANT，T.，LOVE，V.A.，LIRA，P.D.，DOYONNAS，R.，BERGQVIST，S.，BAXI，S.M.，ROHNER，A.，SHEN，A.C.，HUANG，C.，SOKOLOWSKI，S.A.&SHARP，L.L.2012.Targeting of 4-1BB by monoclonal antibody PF-05082566enhances T-cell function and promotes anti-tumor activity.Cancer ImmunolImmunother，61，1721-33.

18.SKERRA，A.2000.Lipocalins as a scaffold.Biochim Biophys Acta，1482，337-50.

19.FLOWER，D.R.，NORTH，A.C.&SANSOM，C.E.2000.The lipocalin proteinfamily：structural and sequence overview.Biochim Biophys Acta，1482，9-24.

20.FLOWER，D.R.1996.The lipocalin protein family：structure andfunction.Biochem J，318(Pt 1)，1-14.

21.ALTSCHUL，S.F.，MADDEN，T.L.，SCHAFFER，A.A.，ZHANG，J.，ZHANG，Z.，MILLER，W.&LIPMAN，D.J.1997.Gapped BLAST and PSI-BLAST：a new generation of proteindatabase search programs.Nucleic Acids Res，25，3389-402.

22.ALTSCHUL，S.F.，GISH，W.，MILLER，W.，MYERS，E.W.&LIPMAN，D.J.1990.Basiclocal alignment search tool.J Mol Biol，215，403-10.

23.SMITH，T.F.&WATERMAN，M.S.1981.Identification of common molecularsubsequences.J Mol Biol，147，195-7.

24.WARD，E.S.，GUSSOW，D.，GRIFFITHS，A.D.，JONES，P.T.&WINTER，G.1989.Binding activities of a repertoire of single immunoglobulin variabledomains secreted from Escherichia coli.Nature，341，544-6.

25.HOLLIGER，P.，PROSPERO，T.&WINTER，G.1993.″Diabodies″：small bivalentand bispecific antibody fragments.Proc Natl Acad Sci USA，90，6444-8.

26.JOHNSON，G.&WU，T.T.2000.Kabat database and its applications：30years after the first variability plot.Nucleic Acids Res，28，214-8.

27.EHRENMANN，F.，KAAS，Q.&LEFRANC，M.P.2010.IMGT/3Dstructure-DB andIMGT/DomainGapAlign：a database and a tool for immunoglobulins or antibodies，Tcell receptors，MHC，IgSF and MhcSF.Nucleic Acids Res，38，D301-7.

28.BULLIARD，Y.，JOLICOEUR，R.，ZHANG，J.，DRANOFF，G.，WILSON，N.S.&BROGDON，J.L.2014.OX40 engagement depletes intratumoral Tregs via activatingFcgammaRs，leading to antitumor efficacy.Immunol Cell Biol，92，475-80.

29.BULLIARD，Y.，JOLICOEUR，R.，WINDMAN，M.，RUE，S.M.，ETTENBERG，S.，KNEE，D.A.，WILSON，N.S.，DRANOFF，G.&BROGDON，J.L.2013.Activating Fc gamma receptorscontribute to the antitumor activities of immunoregulatory receptor-targetingantibodies.J Exp Med，210，1685-93.

30.SILVA，J.P.，VETTERLEIN，O.，JOSE，J.，PETERS，S.&KIRBY，H.2015.The S228Pmutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstratedusing a combination of novel quantitative immunoassays and physiologicalmatrix preparation.J Biol Chem，290，5462-9.

31.GLAESNER，W.，VICK，A.M.，MILLICAN，R.，ELLIS，B.，TSCHANG，S.H.，TIAN，Y.，BOKVIST，K.，BRENNER，M.，KOESTER，A.，PORKSEN，N.，ETGEN，G.&BUMOL，T.2010.Engineeringand characterization of the long-acting glucagon-like peptide-1 analogueLY2189265，an Fc fusion protein.Diabetes Metab Res Rev，26，287-96.

32.DALL′ACQUA，W.F.，KIENER，P.A.&WU，H.2006.Properties of human IgG1sengineered for enhanced binding to the neonatal Fc receptor(FcRn).J BiolChem，281，23514-24.

33.ZALEVSKY，J.，CHAMBERLAIN，A.K.，HORTON，H.M.，KARKI，S.，LEUNG，I.W.，SPROULE，T.J.，LAZAR，G.A.，ROOPENIAN，D.C.&DESJARLAIS，J.R.2010.Enhanced antibodyhalf-life improves in vivo activity.Nat Biotechnol，28，157-9.

34.SHIELDS，R.L.，NAMENUK，A.K.，HONG，K.，MENG，Y.G.，RAE，J.，BRIGGS，J.，XIE，D.，LAI，J.，STADLEN，A.，LI，B.，FOX，J.A.&PRESTA，L.G.2001.High resolution mappingof the binding site on human IgG1 for Fc gamma RI，Fc gamma RII，Fc gamma RIII，and FcRn and design of IgG1 variants with improved binding to the Fc gammaR.J Biol Chem，276，6591-604.

35.ALTSHULER，E.P.，SEREBRYANAYA，D.V.&KATRUKHA，A.G.2010.Generation ofrecombinant antibodies and means for increasing their affinity.Biochemistry(Mosc)，75，1584-605.

36.HARLOW，E.&LANE，D.1999.Using antibodies：a laboratory manual，ColdSpring Harbor，N.Y.，Cold Spring Harbor Laboratory Press.

37.HARLOW，E.&LANE，D.1988.Antibodies：a laboratory manual，Cold SpringHarbor，NY，Cold Spring Harbor Laboratory.

38.LI，J.，SAI，T.，BERGER，M.，CHAO，Q.，DAVIDSON，D.，DESHMUKH，G.，DROZDOWSKI，B.，EBEL，W.，HARLEY，S.，HENRY，M.，JACOB，S.，KLINE，B.，LAZO，E.，ROTELLA，F.，ROUTHIER，E.，RUDOLPH，K.，SAGE，J.，SIMON，P.，YAO，J.，ZHOU，Y.，KAVURU，M.，BONFIELD，T.，THOMASSEN，M.J.，SASS，P.M.，NICOLAIDES，N.C.&GRASSO，L.2006.Human antibodies forimmunotherapy development generated via a human B cell hybridomatechnology.Proc Natl Acad Sci USA，103，3557-62.

39.KOZBOR，D.&RODER，J.C.1983.The production of monoclonal antibodiesfrom human lymphocytes.Immunol Today，4，72-9.

40.COLE，S.P.，CAMPLING，B.G.，LOUWMAN，I.H.，KOZBOR，D.&RODER，J.C.1984.Astrategy for the production of human monoclonal antibodies reactive with lungtumor cell lines.Cancer Res，44，2750-3.

41.HOLLIGER，P.&HUDSON，P.J.2005.Engineered antibody fragments and therise of single domains.Nat Biotechnol，23，1126-36.

42.PERVAIZ，S.&BREW，K.1987.Homology and structure-functioncorrelations between alpha l-acid glycoprotein and serum retinol-bindingprotein and its relatives.FASEB J，1，209-14.

43.SAMBROOK，J.&RUSSELL，D.W.2001.Molecular cloning：a laboratorymanual，Cold Spring Harbor，N.Y.，Cold Spring Harbor Laboratory Press.

44.FLOWER，D.R.2000.Beyond the superfamily：the lipocalinreceptors.Biochim Biophys Acta，1482，327-36.

45.BREUSTEDT，D.A.，KORNDORFER，I.P.，REDL，B.&SKERRA，A.2005.The 1.8-Acrystal structure of human tear lipocalin reveals an extended branched cavitywith capacity for multiple ligands.J Biol Chem，280，484-93.

46.SCHMIDT，T.G.，KOEPKE，J.，FRANK，R.&SKERRA，A.1996.Molecularinteraction between the Strep-tag affinity peptide and its cognate target，streptavidin.J Mol Biol，255，753-66.

47.VAJO，Z.&DUCKWORTH，W.C.2000.Genetically engineered insulin analogs：diabetes in the new millenium.Pharmacol Rev，52，1-9.

48.FUERTGES，F.&ABUCHOWSKI，A.1990.The clinical efficacy of poly(ethylene glycol)-modified proteins.Journal of Controlled Release，11，139-148.

49.DENNIS，M.S.，ZHANG，M.，MENG，Y.G.，KADKHODAYAN，M.，KIRCHHOFER，D.，COMBS，D.&DAMICO，L.A.2002.Albumin binding as a general strategy for improving thepharmacokinetics of proteins.J Biol Chem，277，35035-43.

50.KONIG，T.&SKERRA，A.1998.Use of an albumin-binding domain for theselective immobilisation of recombinant capture antibody fragments on ELISAplates.J Immunol Methods，218，73-83.

51.OSBORN，B.L.，OLSEN，H.S.，NARDELLI，B.，MURRAY，J.H.，ZHOU，J.X.，GARCIA，A.，MOODY，G.，ZARITSKAYA，L.S.&SUNG，C.2002.Pharmacokinetic and pharmacodynamicstudies of a human serum albumin-interferon-alpha fusion protein incynomolgus monkeys.J Pharmacol Exp Ther，303，540-8.

52.LOWMAN，H.B.1997.Bacteriophage display and discovery of peptideleads for drug development.Annu Rev Biophys Biomol Struct，26，401-24.

53.RODI，D.J.&MAKOWSKI，L.1999.Phage-display technology--finding aneedle in a vast molecular haystack.Curr Opin Biotechnol，10，87-93.

54.VENTURI，M.，SEIFERT，C.&HUNTE，C.2002.High level production offunctional antibody Fab fragments in an oxidizing bacterial cytoplasm.J MolBiol，315，1-8.

55.BRUCKDORFER，T.，MARDER，O.&ALBERICIO，F.2004.From production ofpeptides in milligram amounts for research to multi-tons quantities for drugsof the future.Curr Pharm Biotechnol，5，29-43.